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Abstract
Cancer of the urinary bladder is often a result of exposure to chemical carcinogens. Models of this disease have
been developed by exposing rodents to N -butyl-N -(4-hydroxybutyl)-nitrosamine (OH-BBN). The resultant tumors
are histologically similar to human disease, but little is known about genetic similarities to the latter. Such knowl-
edge would help identify or corroborate genes found important in human bladder cancer and suggest biologically
appropriate mechanistic studies. We address this need by comparing gene expression profiles associated with
urothelial carcinoma for three different species: mouse, rat, and human. We find that many human genes homolo-
gous to those differentially expressed in carcinogen-induced rodent tumors are also differentially expressed in
human disease and are preferentially associated with progression from non–muscle-invasive to muscle-invasive
disease. We also find that overall gene expression profiles of rodent tumors correspond more closely with those
of invasive human tumors rather than non–muscle-invasive tumors. Finally, we provide a list of genes that are likely
candidates for driving this disease process by virtue of their concordant regulation in tumors of all three species.
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Introduction
Cancer of the urinary bladder is the fourth most common newly di-
agnosed cancer in men in the United States, with 51,230 new diag-
noses predicted in 2008, and will be responsible for an estimated
14,100 deaths [1]. Most bladder tumors in the western world are
of urothelial (“transitional”) cell histology and are categorized accord-
ing to cellular grade and the extent to which the tumor invades the
surrounding tissues. The prognosis is good for those with non–muscle-
invasive tumors, whereas those with muscle-invasive disease are at in-
creased risk of metastasis and death [2]. Having robust and clinically
relevant animal models for the mechanistic study of the causes under-
lying carcinogenesis, tumor progression, and metastasis of urothelial
carcinoma would improve treatment and prognosis for patients with
bladder cancer.
Many bladder cancers result from exposure to chemical carcino-
gens. It is estimated that one third to one half of bladder tumors
are associated with cigarette smoking [3,4]. Whereas the specific
causative agent in cigarette smoke remains unidentified, α- and β-
naphthylamine are suspected. Occupational exposure to aromatic
amines such as β-naphthylamine, 4-aminobiphenyl, benzidine, and
2-amino-1-naphthol, among other chemicals, accounts for an addi-
tional 20% to 30% of bladder cancer cases in the United States [5,6].
Given the importance of chemical carcinogenesis to the develop-
ment of bladder cancer, we sought to evaluate the degree of molecular
similarity of two commonly used primary rodent models of this disease
to human bladder cancer. Both models involve the administration of
N -butyl-N -(4-hydroxybutyl)-nitrosamine (OH-BBN) to mice [7,8] or
rats [9–11]. Second, if molecular similarity did exist, we sought to de-
termine, by virtue of cross-species comparison, which genes were the
most important in bladder tumor development and progression, thus
providing promising leads for future research. Experiments profiling
the gene expression of normal urothelium and OH-BBN–induced
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bladder tumors in both rat and mice have been published [12,13], pro-
viding an opportunity to address these important questions.
Methods
Human Bladder Cancer Microarrays
We constructed a human bladder cancer gene expression data set
of 53 previously published Affymetrix HG-U133A GeneChips, in-
cluding normal urothelial tissue and both non–muscle-invasive and
muscle-invasive tumors. Data from 30 microarray chips were down-
loaded from the Gene Expression Omnibus Web site (GEO Acces-
sion Number GSE3167) [14–16], whereas those of 23 chips were
obtained locally [17]. The clinical characteristics of the characterized
tissues are summarized in Table 1. Microarray profiles were classi-
fied according to the type of tissue hybridized to the chip. Fifteen
chips were hybridized with RNA from normal urothelium, 14 chips
with non–muscle-invasive bladder tumors (defined as stage Ta
or T1 tumors with grade less than 3), and 24 chips with muscle-
invasive bladder tumors (defined as stage T2 or greater, any grade).
We used the Robust Multichip Average method to quantile-normalize,
background-adjust, and summarize the gene expression values from
these chips [18–20].
Rodent Bladder Cancer Microarrays
Yao et al. [12] found 1554 mouse genes differentially expressed
between bladder cancer and normal urothelial tissue with a t test
P value < .05 and fold change ≥ 2, 867 of which were overexpressed
and 687 underexpressed in the tumors. They published 53 over-
expressed and 37 underexpressed genes along with fold change values.
In a similar study, they found 1138 rat genes to be differentially ex-
pressed with a t test P value < .05 and fold change ≥ 2, 770 of which
were overexpressed and 368 underexpressed in the tumors. They pub-
lished 98 overexpressed and 47 underexpressed genes or transcripts
with fold change values [13].
Homology and Statistical Analysis of Bladder
Cancer Microarrays
We used the NetAffx information site (http://www.affymetrix.com)
to determine which human Affymetrix HG-U133A probe sets were
homologous with the published rodent genes [21] (Figure 1A). Be-
cause Yao et al. [12] used Affymetrix MG-U74Av2 and Rat 230 2.0
GeneChips to measure gene expression in the normal and cancerous
tissues, we first determined which MG-U74Av2 probe sets corre-
spond to the accession numbers of the listed mouse genes and which
Rat 230 2.0 probe sets correspond to the listed rat genes or transcript
accession numbers. We then found the HG-U133A probe sets that
were homologous to these matched mouse and rat genes. Some rodent
genes had multiple human homologs, whereas others had none. No
human probe sets were homologous to more than one mouse or rat
gene, with the exception of 201429_s_at and 202240_at, which were
homologous to Plk and Plk-ps1. Because Plk-ps1 is a pseudogene, we
used the fold change value for Plk in subsequent analyses. For simplic-
ity, we refer to the human probe sets homologous to the genes differ-
entially expressed between tumor and normal bladder in the rodent as
“mouse homologs” and “rat homologs” respectively and collectively as
“rodent homologs”.
To examine the importance of individual rodent homologs to trans-
formation (normal vs cancer) and progression in humans, we first used
Student’s t test to determine the significance of the difference in ex-
pression between normal urothelium and non–muscle-invasive cancer,
between normal urothelium and muscle-invasive cancer, between
non–muscle-invasive and muscle-invasive cancer, and between normal
and cancerous urothelium, for the 53 chips in the human bladder
microarray data set. Thus, for every homologous probe set, there were
four different P values representing the significance level of the afore-
mentioned tests. (We considered genes to be significantly differentially
expressed if at least half of their corresponding probe sets are signifi-
cantly differentially expressed in the same direction, unless there are
other probe sets significantly differentially expressed in the opposite di-
rection.) To gain more insight into the meaning of these nominal sig-
nificance values, we additionally calculated the significance of the
difference in expression for the remaining 21,873 probe sets on the
HG-U133A chips for the four different comparisons described previously.
To determine whether the rodent homologs were enriched with
genes significant to human disease progression, we used two similar
statistical techniques. First, we performed a one-sided Kolmogorov–
Smirnov (KS) test to compare the P value distribution of the ho-
mologous probe sets to the P value distribution of all 22,215 probe
sets found on the 53 HG-U133A chips profiling human bladder can-
cer tissue. To estimate false discovery rate (FDR) Q values for the
KS tests, we performed the KS test on 1000 groups of randomly se-
lected probe sets (with the same number of probe sets as in the
groups of rodent homologs) to generate a distribution of random
KS test P values. We then used the R package qvalue to estimate
the Q value for the KS test involving the rodent homologs, using
the 1000 random KS P values and the rodent homolog KS P value
as input. We also used the Gene Set Enrichment Analysis (GSEA)
program (version 2.0) [22–24] to test the rodent homologs for en-
richment with significantly and differentially expressed probe sets
in the 53 human samples categorized as previously mentioned, using
the t test as the gene-ranking method, without collapsing the data set
to gene symbols.
To determine whether the patterns of expression in rodent bladder
tumors are more similar to those of invasive or noninvasive human
cancers, we calculated human expression fold change values for each
non–muscle-invasive or muscle-invasive tumor chip by dividing the
expression value of an individual probe set by the average expression of
all the normal urothelial chips for that probe set. We then generated a
“mouse” or “rat” expression profile by assigning the fold change values
(from the rodent normal vs tumor comparison) for a particular mouse
or rat gene to all human probe sets homologous to that gene. We then
performed hierarchical clustering analysis of the “rodent” profile and
human tumor profiles. To improve the distinction between the clusters
Table 1. Stage and Grade of Human Bladder Cancer Specimens.
Stage Grade (1–4) N
Normal n/a 15
Ta 1 1
Ta 2 10
T1 2 3
T2 2 1
T2 3 4
T3 3 6
T3 4 3
T4 2 1
T4 3 9
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of non–muscle-invasive and muscle-invasive tumors, we only clustered
probe sets with significant (P < .1) differences between non–muscle-
invasive and muscle-invasive expression.
Results
Evaluation of Rodent Homologs as a Function of Malignancy
We first determined the human homologs of the rodent genes
using NetAffx, as described in the Methods section; these are listed
in Table W1. We found that the 90 originally published mouse genes
correspond to 94 MG-U74Av2 probe sets and that the 145 originally
published rat genes correspond to 173 Rat 230 2.0 probe sets. We
subsequently found 144 unique human HG-U133A probe sets ho-
mologous to the 94 mouse probe sets and 223 unique human
HG-U133A probe sets homologous to the 173 rat probe sets. Twenty-
five human probe sets were homologous to genes that were differen-
tially expressed in both rat and mouse. We were unable to find human
probe sets homologous to nine mouse genes, and as mentioned in the
Methods section, we ignored Plk-ps1 due to its pseudogenous nature;
thus, analyses were performed on homologs of 80 mouse genes
Figure 1. (A) Diagrammatic representation of the analysis workflow and results. (B) Venn diagrams showing the numbers of genes
differentially regulated in human, mouse, and rat and concordantly regulated. Shown are genes overexpressed or underexpressed in
tumors compared to normal urothelium. Asterisk (*) indicates genes whose pattern of expression is shown in Figure 2.
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corresponding to 83 MG-U74Av2 probe sets. Similarly, we were un-
able to find human probe sets homologous to 35 rat genes; thus, anal-
yses were performed on 110 rat genes corresponding to 138 Rat 230
2.0 probe sets.
We then examined how expression levels of rodent homologs
changed according to human bladder state (normal, non–muscle-
invasive, and muscle-invasive). After classifying the tissue samples into
normal and malignant urothelium, we examined the differential ex-
pression between each pair of these three groups of tissues, using Stu-
dent’s t test. The numbers of probe sets and corresponding genes that
were significantly (P < .05) differentially expressed between normal
urothelium and urothelial carcinomas were computed. We found
that 52 (65%) of 80 mouse homologs [86 (60%) of 144 probe sets]
and 71 (63%) of 112 rat homologs [138 (62%) of 223 probe sets]
were significantly differentially regulated between human normal ur-
othelium and urothelial carcinoma (of any grade or stage). We fur-
ther found that of 11 genes homologous among all three species,
namely, human, rat, and mouse, 9 genes (82%), or 18 (72%) of
25 probe sets, were similarly differentially expressed.
Identification of Interspecies Concordant Homologs in
Transformation and Progression
In Figure 1B, we show the numbers of homologous genes that are
significantly differentially expressed between normal and cancerous
Figure 2. Patterns of expression for genes differentially regulated in human, mouse, and rat bladder tumors as a function of human
bladder state. The average normalized log2(gene expression) value for normal urothelium, non–muscle-invasive and muscle-invasive
cancers are plotted for each tissue type. Data for all significantly and differentially expressed probe sets for the genes identified with
an asterisk (*) in Figure 1B are plotted here. Line color codes relate to the gene expression pattern as a function of tumorigenicity and
progression as shown in Table 2 (genes in bold). For example, genes with red lines are significantly differentially expressed between
normal urothelium and noninvasive tumor and between noninvasive tumor and invasive human tumor.
Table 2. Genes Differentially Regulated with Increasing Invasiveness in Human Bladder Cancer and Concordant in Expression with the Corresponding Rodent Homolog.
Expression Pattern Mouse Homologs Rat Homologs
Positively correlated with transformation* and invasiveness CCNB2, CDC2, CDC20, CKS1B, MAD2L1, NMI, RACGAP1,
RAD51, TFDP1
BUB1B, CCNB1, CCNB2, CDC2, CDC20, ECT2, MAD2L1,
RACGAP1
Negatively correlated with transformation invasiveness N/A N/A
Significantly increased in cancer, no significant change with
invasiveness
CCNE1, PIK3CA, RAN, RHOG, RIN2 DUSP6, PYCARD
Significantly decreased in cancer, no significant change with
invasiveness
ARHGDIG, GATA4, MAP2K6, SH3BGR, SH3GL2, SH3GL3 HRASLS, LGI1, PAK3, PPARA, WT1
Significantly increased in non–muscle-invasive disease only CCND1, MKNK1, RAD9A, SKAP2 AKT1, ARHGAP8, BCL6, CCND1, IGFBP3, IGFBP4, NDRG4
Significantly decreased in non–muscle-invasive disease only GAS1 CARD9, CDKN1C, FGFR2, FRS2, NTRK1, PDGFRL, RASA3,
RORA, SNFT
Significantly increased in muscle-invasive disease only CCNA2, CRELD2, FOXM1, MAP4K4, NFKBIE CCNA2, CDCA3, CDKN2A, CDKN2C, CDKN3, KIF20A,
MKI67, RAP2B
Significantly decreased in muscle-invasive disease only GATA2, LMO1, NDRG2, SH2B1, TCF2, TCF21, TCF7L1 CYP11A1, CYP3A43, FHIT, NDRG2, RAB27B, RORC
Symbols in bold indicate homology with both rat and mouse (eight genes corresponding to the central regions in Figure 1B and whose expressions are graphed in Figure 2).
*Defined as the difference between normal and cancer.
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urothelium in all three species. Of 80 human homologs of the genes
differentially expressed in mouse tumors, 55 genes were significantly
differentially expressed in human (P < .05). However, of those 55
genes, only 31 were concordantly regulated; in other words, the di-
rection of the change in expression in bladder tumors was the same in
both species. Similarly, of 112 human homologs of the published rat
genes, 74 were significantly differentially expressed in humans; 41 of
these genes were concordantly regulated in both species. Few genes
were differentially expressed and were concordantly regulated in all
three species—seven genes were overexpressed and one was repressed.
The patterns of gene expression for these eight genes (corresponding
to the central regions in Figure 1B) are shown in Figure 2. Interest-
ingly, for most of these genes, the expression level is correlated with
invasiveness; NDRG2 is the sole gene to decrease expression with in-
creasing invasiveness. Two genes (CCNA2 and CCND1) are signifi-
cantly up-regulated only in invasive tumors (compared to noninvasive)
and in noninvasive tumors (compared to invasive), respectively.
To better understand the contribution of individual rodent homo-
logs to human disease and progression, a similar analysis was per-
formed for all rodent homologs. A complete list of human genes
that are both homologous to and concordantly regulated with either
mouse or rat is shown in Table 2. These genes are further classified
according to different trends of significant differential expression
with invasiveness. In Tables 3 and 4, these genes are listed as a func-
tion of the ontologies of the rodent homologs and indicate that genes
associated with disease progression are associated with the cell cycle,
transcription regulation, or the Ras and EGFR pathways.
Gene Enrichment Analysis Suggests Rodent Tumors Reflect the
Molecular Profile of Human Cancer
To determine whether rodent homologs were significantly en-
riched with genes significant to human bladder cancer, we performed
two separate but similar analyses. First, we applied the KS test to
compare the distributions of t test P values between the rodent
homologs and all 22,215 probe sets on the HG-U133A chips. We
also used the GSEA program; because the GSEA program does not
yet support testing gene sets with both up- and down-regulated
genes, we split our gene sets into up- and down-regulated sets and
ran the analysis for these split sets. The P values and FDR Q values
for the KS tests and the GSEA tests are listed in Table 5.
The KS test results suggest that although the rodent homologs are
not significantly associated with the initial development of human
cancer, they are associated with the progression between non–muscle-
invasive and muscle-invasive tumors. The results from GSEA tests are
more complex: they support the KS test observation that rodent homo-
logs are significantly associated with invasiveness, but the results also
suggest that these genes are associated with the development of human
tumors. (The small number of genes significantly down-regulated in all
species may be the reason the down-regulated sets are not significantly
Table 3. Gene Ontology of Mouse Homologs Differentially Expressed between Normal Human Urothelium and Cancer, Listed in Table 2.
Classification Gene
Overexpressed in human muscle-invasive disease
Cell cycle–related CCNA2 (Ccna2), CCNB2 (Ccnb2), CCND1 (Ccnd1), CCNE1 (Ccne1), CDC2 (CDC2a), CDC20 (CDC20), CKS1B (Cks1),
MAD2L1 (Mad2l1), TFDP1 (Dp1)
EGF/EGFR pathway MAP4K4 (Map4k4), PIK3CA (Pik3ca), SKAP2 (Scap2)
Ras pathway RACGAP1 (Racgap1), RAD51 (Rad51), RAD9A (Rad9), RAN (Rasl2–9), RHOG (Ahrg), RIN2 (Rin2)
Transcription regulators CRELD2 (Etv6 ), FOXM1 (Foxm1), MKNK1 (Mknk1), NFKBIE (Nfkbie), NMI (Nmi)
Underexpressed in human muscle-invasive disease
Cell cycle–related GAS1 (Gas1)
MAPK/SRC pathway MAP2K6 (Map2k6), SH2B1 (Sh2bpsm1), SH3BGR (Sh3bgr), SH3GL2 (Sh3gl2), SH3GL3 (Sh3gl3)
Ras pathway ARHGDIG (Arhgdig)
Transcription regulators GATA2 (Gata2), GATA4 (Gata4), LMO1 (Lmo1), NDRG2 (Ndr2), TCF2 (Tcf2), TCF21 (Tcf21), TCF7L1 (Tcf3)
Gene symbols in parentheses represent the homologous mouse gene. Symbols in bold indicate homology with both rat and mouse (eight genes corresponding to the central regions in Figure 1B and
whose expressions are graphed in Figure 2).
Table 4. Gene Ontology of Rat Homologs Differentially Expressed between Normal Human Urothelium and Cancer, as Listed in Table 2.
Classification Gene
Overexpressed in human muscle-invasive disease
Apoptosis PYCARD (Pycard )
Cell cycle–related CCNA2 (Ccna2), CCNB1 (Ccnb1), CCNB2 (Ccnb2), CCND1 (Ccnd1), CDC2 (Cdc2a), CDC20 (Cdc20), CDCA3 (Cdca3), CDKN2A
(Cdkn2a), CDKN2C (Cdkn2c), CDKN3 (Cdkn3), DUSP6 (Dusp6), KIF20A (Cdc23), MAD2L1 (Mad2l1), MKI67 (Mki67 )
Growth factors IGFBP3 (Igfbp3), IGFBP4 (Igfbp4 )
Oncogenes ETC2 (Etc2), NDRG4 (Ndr4 )
Small G-proteins RACGAP1 (Racgap1), RAP2B (Rap2b)
Underexpressed in human muscle-invasive disease
Apoptosis NTRK1 (Ntrk1)
Cell cycle–related CDKN1C (Cdkn1c), PPARA (Ppara), SNFT ( Jundp1)
Growth factors FGFR2 (FGFR2), FRS2 (BE112403), PDGFRL (BM384311)
Oncogenes FHIT (Fhit), HRASLS (AI548958), NDRG2 (Ndrg2), PAK3 (Pak3), WT1 (Wt1)
Others CYP11A1 (Cyp11a1), CYP3A43 (Cyp3a18), LGI1 (Lgi1), RORA (AI235414), RORC (BE110171)
Small G-proteins RAB27B (Rab27b), RASA3 (Rasa3)
Gene symbols or accession numbers in parentheses represent the homologous rat gene. Symbols in bold indicate homology with both rat and mouse (eight genes corresponding to the central regions in
Figure 1B and whose expressions are graphed in Figure 2).
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enriched.) There are other significant findings as well; in particular, the
rat homologs seem to be associated with the initial development of
noninvasive human tumors. In general, it is clear that the rodent homo-
logs are indeed relevant to human disease.
Rodent Tumors Have More Molecular Similarity to Invasive
Rather Than Noninvasive Human Tumors
To determine whether these rodent models are more relevant for
the study of noninvasive or invasive human disease, we performed
unsupervised hierarchical clustering of expression fold changes be-
tween cancerous and normal tissues for the rodent homologs, where
all probe sets homologous to a particular rodent gene are assigned the
published fold change values [12,13] or the fold change as a function
of tumor stage in the human samples (Table 1). The clusters for the
mouse and rat homologs are shown in Figure 3, A and B, respectively.
Figure 3A shows that the mouse homologs cluster into two main
groups when human tumor stage data are used: one includes a mix-
ture of non–muscle-invasive and muscle-invasive tumors, whereas
the other is made up of exclusively muscle-invasive tumors. The
“mouse” fold change profile derived from the rodent genes differen-
tially expressed as a function of transformation clusters closely with
this latter group, showing that the induced mouse tumors have a
similar gene expression to a subset of human invasive tumors. Fig-
ure 3B shows the “rat” fold change profile clusters with most of
the invasive human tumors. Together, these data suggest that rodent
bladder tumors have gene expression profiles more similar to those of
human invasive than noninvasive tumors and thus would be a better
experimental model for the former.
Discussion
We have previously studied genes differentially regulated in meta-
static human bladder cancer xenografts in mice to gain insight into
regions of the chromosome involved in bladder cancer metastasis
[25]. In this article, we study human homologs of rodent genes dif-
ferentially expressed in chemical-induced animal models of bladder
cancer. The comparison of evolutionarily conserved genes in different
species is a frequently used technique–sequence alignments and com-
parative genomics analyses are often used to infer the function or
evolutionary origin of a gene or protein, for example. Cross-species
comparative expression profiling is relatively new, however, although
it seems intuitive that genes with evolutionarily conserved sequences
ought to have somewhat similar functions and should presumably be
regulated in similar ways. Comparison of the tumor-related expres-
sion patterns of homologous genes in animal models of human can-
cers has been used to study the relevance of liver cancer in zebrafish
to human liver [26], to evaluate seven different mouse models of
hepatocellular carcinoma to find the most appropriate for liver cancer
in humans [27], to compare a transgenic mouse model of lung cancer
with a variety of human lung cancers [28], and to analyze several
mouse models of breast cancer [29].
In the present study, we examined the patterns of gene expression
involved in bladder cancer for three different species. Whereas others
have studied a variety of animal models of human cancer [26–29]
(including bladder [28]), here we focus on bladder cancer and com-
pare the molecular profiles of carcinogen-induced rodent tumors
with that of human disease. The carcinogenesis models are particu-
larly relevant comparators and models because human bladder cancer
is often a result of chemical carcinogenesis. Interestingly, we found
that a significant proportion of rodent homologs exhibit significant
differences in gene expression between non–muscle-invasive and
muscle-invasive disease in humans. Furthermore, we determined that
the induced rodent tumors exhibit more similarity of gene expression
to human muscle-invasive disease than noninvasive disease, which is
consistent with their muscle-invasive pathology.
Comparative genomic profiling across species can be divided into
two steps: first, one determines whether genes important for a par-
ticular condition in one species are important in the other; second,
one can determine the degree to which the patterns of gene expres-
sion are similar. We found that most human genes homologous to
genes differentially expressed (vs normal) in bladder tumors in both
mouse and rat were also significantly and differentially expressed (vs
normal) in human tumors, suggesting that these homologous genes
are indeed significant to human cancer. To quantify this with more
statistical rigor, we performed KS and GSEA tests to examine the
enrichment of significantly and differentially expressed genes among
rodent homologs. We clearly found that these sets of human homo-
logs were enriched with genes significantly differentially expressed
between superficial and muscle-invasive bladder tumors. By focusing
on genes that are consistently and concordantly expressed in bladder
cancer in three species, we can be confident that such genes are ro-
bust candidates for proteins that are biologically important in human
bladder carcinogenesis and progression.
Many of the genes differentially expressed between normal urothelium
and urothelial cancer in all three species are associated with the cell
cycle. For instance, cell division cycle 20 (CDC20), cell division cycle 2
(CDC2), cyclins D1 and B2 (CCND1 and CCNB2), mitotic arrest–
deficient 2, Saccharomyces cerevisiae, homolog-like 1 (MAD2L1), and
cyclin A2 (CCNA2) are all associated with progression through the cell
cycle. CDC20 activates the anaphase-promoting complex [30],
CCNB2 activates CDC2 [31], which promotes entry into metaphase
[32,33], MAD2L1 is involved with the mitotic spindle checkpoint
Table 5. Kolmogorov–Smirnov and GSEA P values and FDR Q values (in Parentheses) Showing the Significance of Enrichment of Sets of Rodent Homologous Genes with Probe Sets Significantly
Differentially Expressed in Human Cancer.
Normal vs Cancer Normal vs Non–Muscle-Invasive Normal vs Muscle-Invasive Noninvasive vs Muscle-Invasive
KS GSEA KS GSEA KS GSEA KS GSEA
Mouse Down 0.323 (0.989) 0.0383 (0.0713) 0.254 (1) 0.0564 (0.109) 0.151 (0.974) 0.0998 (0.448) 6 × 10−7 (0.0006) 0 (0.00556)
Up 0 (0.0824) 0.008 (0.312) 0.0183 (0.0947) 0 (0.00972)
Rat Down 0.896 (0.976) 0.0476 (0.0564) 0.320 (0.999) 0.0269 (0.0576) 0.769 (0.947) 0.0646 (0.653) 5 × 10−4 (0.114) 0 (0.00478)
Up 0.00963 (0.0649) 0.0463 (0.154) 0.00403 (0.0603) 0 (0.00321)
Intersection Down 0.047 (0.919) 0.278 (0.273) 0.484 (1) 0.285 (0.325) 0.028 (1) 0.372 (0.701) 2 × 10−4 (0.163) 0.259 (0.323)
Up 0.0286 (0.155) 0.200 (0.227) 0.0332 (0.0778) 0.042 (0.141)
Numbers in bold represent statistically significant (FDR < 0.2) results.
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Figure 3. Hierarchical clustering of rodent homologs with human cancer. Fold changes between gene expression values in human non–
muscle-invasive and muscle-invasive tumors are hierarchically clustered with “mouse” (A) and “rat” (B) gene expression profiles. The
probe sets in the “rodent” gene profiles are assigned published [12,13] fold change values (cancer vs normal) corresponding to the
homologous rodent genes. Probe sets overexpressed in cancer are colored red, whereas underexpressed probe sets are colored green.
HG-U133A probe sets are listed on the right, the stage and grade of the tumors characterized on the chips are shown on the bottom,
and the color bar near the top of the figure represents the classification of the tumor: red indicates non–muscle-invasive tumors, blue
indicates muscle-invasive tumors, and green indicates the mouse (A) or the rat profile (B).
844 Transcriptomes of Bladder Cancer Models Williams et al. Neoplasia Vol. 10, No. 8, 2008
[34], and CCNA2 promotes entry into synthesis and metaphase
[35]. Other genes differentially expressed in bladder tumors in all
three species include RAC GTPase–activating protein 1 (RACGAP1),
which deactivates RAC proteins and is overexpressed in tumors, and
N-myc downstream-regulated gene 2 (NDRG2), which is under-
expressed in tumors. NDRG2 is a member of the NDRG family, of
which NDRG1 is associated with apoptosis [36]. Furthermore, all,
with the exception of NDRG2, are differentially expressed between
non–muscle-invasive and muscle-invasive human tumors. These genes
are overexpressed in muscle-invasive disease, with the exception of
CCND1, which is underexpressed. Lindgren et al. [37] mentioned that
CDC2, CCNB2, BUB1, andMAD2L1 are in a cell cycle– and mitosis-
related cluster of genes, which correlated expression with tumor pro-
gression. Blaveri et al. [38] said that CCNA2 and CDC2 were more
highly expressed in a cluster of high-grade pTa and pT1 tumors than
in a cluster of mainly low-grade pTa tumors, suggesting that the tu-
mors in the first cluster were more aggressive. These corroborate our
findings that the mouse and rat homologs are indeed important to
bladder cancer.
Finally, through unsupervised hierarchical clustering of fold change
profiles, we determined that rodent bladder tumors are closely as-
sociated with muscle-invasive human tumors. This suggests that
such rodent tumors are good models for the mechanistic study of
genes putatively involved in invasive and metastatic bladder cancer,
especially those that are concordantly expressed in bladder cancer in
three species.
In conclusion, this work suggests that carcinogen-induced rodent
models of urothelial cancer share genetic similarities with pathways
relevant to the development of muscle invasive human disease and
provide genes that are candidate drivers or biomarkers of this process.
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Table W1. Rodent Accession Numbers and/or Gene Symbols with Their Corresponding Affymetrix Mouse MG-74Av2 or Rat 230 2.0 Probe Sets, Matched with Their Orthologous Human HG-U133A
Probe Sets and Corresponding Human Gene Symbols.
Mouse Accession
Number
Mouse Gene
Symbol
Mouse MG-74Av2
Probe Set
Human HG-U133A
Probe Set
Human Gene
Symbol
U73198 Arhgdig 102677_at 206888_s_at ARHGDIG
U58203 Arhgef1 98001_at 203055_s_at ARHGEF1
U19118 Atf3 104155_f_at 202672_s_at ATF3
U43678 Atm 101180_at 210858_x_at ATM
U43678 Atm 101180_at 208442_s_at ATM
U43678 Atm 101180_at 212672_at ATM
AF002823 Bub1 104097_at 209642_at BUB1
AF002823 Bub1 104097_at 216277_at BUB1
AF002823 Bub1 104097_at 216275_at BUB1
AF002823 Bub1 104097_at 215509_s_at BUB1
AF002823 Bub1 104097_at 215508_at BUB1
X75483 Ccna2 99186_at 213226_at CCNA2
X75483 Ccna2 99186_at 203418_at CCNA2
X66032 Ccnb2 94294_at 202705_at CCNB2
AI849928 Ccnd1 94232_at 208712_at CCND1
AI849928 Ccnd1 94232_at 208711_s_at CCND1
X75888 Ccne1 103034_at 213523_at CCNE1
L49507 Ccng1 160127_at 208796_s_at CCNG1
M38724 CDC2a 100128_at 203213_at CDC2
M38724 CDC2a 100128_at 210559_s_at CDC2
M38724 CDC2a 100128_at 203214_x_at CDC2
AW061324 CDC20 96319_at 202870_s_at CDC20
L16926 CDC25c 102934_s_at 205167_s_at CDC25C
L16926 CDC25c 102934_s_at 217010_s_at CDC25C
L16926 CDC25c 102934_s_at 216914_at CDC25C
AB025409 Cks1 97468_at 201897_s_at CKS1B
AF005423 Clk4 101937_s_at 210346_s_at CLK4
AI845538 Etv6 160119_at 218358_at CRELD2
AW049716 Egfr 101842_g_at 201983_s_at EGFR
AW049716 Egfr 101842_g_at 201984_s_at EGFR
AW049716 Egfr 101842_g_at 211607_x_at EGFR
AW049716 Egfr 101842_g_at 210984_x_at EGFR
AW049716 Egfr 101842_g_at 211551_at EGFR
AW049716 Egfr 101842_g_at 211550_at EGFR
AI844939 Cri1 99191_at 211698_at EID1
AI844939 Cri1 99191_at 208669_s_at EID1
AI844939 Cri1 99191_at 208670_s_at EID1
Z36885 Elk4 98732_at 206919_at ELK4
Z36885 Elk4 98732_at 205994_at ELK4
L10426 Etv1 92927_at 221911_at ETV1
L10426 Etv1 92927_at 206501_x_at ETV1
L10426 Etv1 92927_at 217061_s_at ETV1
L10426 Etv1 92927_at 217053_x_at ETV1
X63190 Etv4 92979_at 211603_s_at ETV4
AF017128 Fosl1 99835_at 204420_at FOSL1
AV251191 Foxc2 162016_f_at 214520_at FOXC2
Y11245 Foxm1 98306_g_at 202580_x_at FOXM1
AV138783 Gadd45b 161666_f_at 207574_s_at GADD45B
AV138783 Gadd45b 161666_f_at 209305_s_at GADD45B
AV138783 Gadd45b 161666_f_at 209304_x_at GADD45B
AV138783 Gadd45b 161666_f_at 213560_at GADD45B
X65128 Gas1 94813_at 204456_s_at GAS1
X65128 Gas1 94813_at 204457_s_at GAS1
AB000096 Gata2 102789_at 209710_at GATA2
AB000096 Gata2 102789_at 210358_x_at GATA2
AB000096 Gata2 102789_at 207954_at GATA2
X55123 Gata3 100924_at 209602_s_at GATA3
X55123 Gata3 100924_at 209603_at GATA3
X55123 Gata3 100924_at 209604_s_at GATA3
M98339 Gata4 102713_at 205517_at GATA4
X12761 Jun 100130_at 201464_x_at JUN
X12761 Jun 100130_at 201466_s_at JUN
X12761 Jun 100130_at 201465_s_at JUN
X12761 Jun 100130_at 213281_at JUN
AW122780 Lasp1 93793_at 200618_at LASP1
AW124311 Lmo1 102413_at 206718_at LMO1
AF074600 Lmo4 98122_at 209205_s_at LMO4
AF074600 Lmo4 98122_at 209204_at LMO4
U83902 Mad2l1 99632_at 203362_s_at MAD2L1
U39066 Map2k6 102828_at 205698_s_at MAP2K6
U39066 Map2k6 102828_at 205699_at MAP2K6
AV270901 Map3k4 161568_f_at 216199_s_at MAP3K4
Mouse Accession
Number
Mouse Gene
Symbol
Mouse MG-74Av2
Probe Set
Human HG-U133A
Probe Set
Human Gene
Symbol
AV270901 Map3k4 161568_f_at 204089_x_at MAP3K4
AV341985 Map3k8 161768_r_at 205027_s_at MAP3K8
U88984 Map4k4 102195_at 206571_s_at MAP4K4
U88984 Map4k4 102195_at 218181_s_at MAP4K4
D87271 Erk2 93253_at 212271_at MAPK1
D87271 Erk2 93253_at 208351_s_at MAPK1
L35236 Mapk10 100470_at 204813_at MAPK10
Y11091 Mknk1 92464_at 209467_s_at MKNK1
AV277546 Rhoip3 162066_f_at 212197_x_at M-RIP
AV277546 Rhoip3 162066_f_at 214771_x_at M-RIP
AV277546 Rhoip3 162066_f_at 214694_at M-RIP
AB033921 Ndr2 96088_at 214279_s_at NDRG2
AB033921 Ndr2 96088_at 214278_s_at NDRG2
AB033921 Ndr2 96088_at 206453_s_at NDRG2
M57999 Nfkb1 98427_s_at 209239_at NFKB1
AF030896 Nfkbie 101727_at 203927_at NFKBIE
AF019249 Nmi 101424_at 203964_at NMI
D50264 Arhq 101466_at 205077_s_at PIGF
D50264 Arhq 101466_at 205078_at PIGF
U52193 Pik3c2a 92311_s_at 213070_at PIK3C2A
U03279 Pik3ca 92452_at 204369_at PIK3CA
U01063 Plk 93099_f_at 202240_at PLK1
U01063 Plk 93099_f_at 201429_s_at PLK1 (RPL37A)
AI853996 Rab11a 96238_at 200863_s_at RAB11A
AI853996 Rab11a 96238_at 200864_s_at RAB11A
AW208630 Rab33b 97058_f_at 221014_s_at RAB33B
AB027290 Rab9 95516_at 221808_at RAB9A
AA967636 Rac3 104180_at 206103_at RAC3
AW122347 Racgap1 94953_at 222077_s_at RACGAP1
D13803 Rad51 104527_at 205024_s_at RAD51
D13803 Rad51 104527_at 205023_at RAD51
AF045663 Rad9 93522_at 204828_at RAD9A
L32752 Rasl2-9 102821_s_at 200750_s_at RAN
L32752 Rasl2-9 102821_s_at 200749_at RAN
X56045 Ranbp1 98573_r_at 202483_s_at RANBP1
X56045 Ranbp1 98573_r_at 202482_x_at RANBP1
X56045 Ranbp1 98573_r_at 221915_s_at RANBP1
AF106070 Rasgrp1 98307_at 205590_at RASGRP1
U35142 Rbbp7 93081_at 201092_at RBBP7
U36799 Rbl2 95617_at 212332_at RBL2
U36799 Rbl2 95617_at 212331_at RBL2
X99963 Rhob 101030_at 212099_at RHOB
AB025943 Ahrg 97927_at 203175_at RHOG
AA739233 Ahrh 103231_at 204951_at RHOH
AI835968 Rin2 160827_at 209684_at RIN2
U73941 Rap2ip 103960_at 206196_s_at RPIP8
U73941 Rap2ip 103960_at 213439_x_at RPIP8
AF020526 Sh2bpsm1 101843_at 40149_at SH2B1
AF020526 Sh2bpsm1 101843_at 209322_s_at SH2B1
AW048272 Sh3bgr 96205_at 204979_s_at SH3BGR
X87671 Sh3bp1 92666_at 213633_at SH3BP1
U58886 Sh3gl2 92673_at 205751_at SH3GL2
U58887 Sh3gl3 101412_at 205637_s_at SH3GL3
U58887 Sh3gl3 101412_at 205636_at SH3GL3
U58887 Sh3gl3 101412_at 211565_at SH3GL3
AB014485 Scap2 102012_at 204362_at SKAP2
AB014485 Scap2 102012_at 216899_s_at SKAP2
AB014485 Scap2 102012_at 204361_s_at SKAP2
U29056 Sla 99876_at 203761_at SLA
U29056 Sla 99876_at 203760_s_at SLA
U60530 Madh2 104536_at 203077_s_at SMAD2
U60530 Madh2 104536_at 203075_at SMAD2
U60530 Madh2 104536_at 203076_s_at SMAD2
U15566 Tbx2 92705_at 40560_at TBX2
U15566 Tbx2 92705_at 213417_at TBX2
U15566 Tbx2 92705_at 205993_s_at TBX2
AB008174 Tcf2 101396_at 208135_at TCF2
AB008174 Tcf2 101396_at 205313_at TCF2
AF035717 Tcf21 103050_at 204931_at TCF21
AJ223069 Tcf3 160780_at 221016_s_at TCF7L1
AF043939 Dp1 97565_r_at 212330_at TFDP1
AF043939 Dp1 97565_r_at 204147_s_at TFDP1
Table W1. (continued )
Rat Accession
Number
Rat Gene Symbol Rat 230 2.0
Probe Set
Human HG-U133A
Probe Set
Human Gene Symbol
NM_033230 Akt1 1383126_at 207163_s_at AKT1
NM_031575 Akt3 1387592_at 219393_s_at AKT3
NM_031575 Akt3 1387592_at 212609_s_at AKT3
NM_031575 Akt3 1387592_at 212607_at AKT3
BE111827 Arhgap4 1374735_at 204425_at ARHGAP4
AA945062 Arhgap8 1376501_at 37117_at ARHGAP8
AA945062 Arhgap8 1376501_at 205980_s_at PRR5
BF285771 Arhgdib 1373881_at 201288_at ARHGDIB
BG377320 1373541_at 203756_at ARHGEF17
BE116855 Bcl11b 1384944_at 219528_s_at BCL11B
NM_133416 Bcl2a1 1368482_at 205681_at BCL2A1
AI411774 Bcl3 1398482_at 204908_s_at BCL3
AI411774 Bcl3 1398482_at 204907_s_at BCL3
AI237606 Bcl6 1379368_at 203140_at BCL6
AI237606 Bcl6 1379368_at 215990_s_at BCL6
NM_023987 Birc2 1370113_at 210538_s_at BIRC3
AI227742 Bok 1373733_at 221454_at BOK
BF396613 Brca2 1381141_at 208368_s_at BRCA2
BF396613 Brca2 1381141_at 214727_at BRCA2
BF388785 Bub1 1385086_at 209642_at BUB1
BF388785 Bub1 1385086_at 216277_at BUB1
BF388785 Bub1 1385086_at 216275_at BUB1
BF388785 Bub1 1385086_at 215509_s_at BUB1
BF388785 Bub1 1385086_at 215508_at BUB1
BF557145 Bub1b 1383926_at 203755_at BUB1B
NM_022303 LOC64171 1368637_at 220162_s_at CARD9
BI303370 Rad51 1395480_at 220247_at CASC5
D85899 Casp1 1369186_at 211368_s_at CASP1
D85899 Casp1 1369186_at 211367_s_at CASP1
D85899 Casp1 1369186_at 211366_x_at CASP1
D85899 Casp1 1369186_at 209970_x_at CASP1
D85899 Casp1 1369186_at 206011_at CASP1
NM_053736 Casp11 1387818_at 209310_s_at CASP4
NM_053736 Casp11 1387818_at 213596_at CASP4
NM_053736 Casp11 1387818_at 208340_at CASP4
AA998516 Ccna2 1379582_a_at 213226_at CCNA2
AA998516 Ccna2 1379582_a_at 203418_at CCNA2
X64589 Ccnb1 1370346_at 214710_s_at CCNB1
AW253821 Ccnb2 1389566_at 202705_at CCNB2
X75207 Ccnd1 1371150_at 208712_at CCND1
X75207 Ccnd1 1371150_at 208711_s_at CCND1
NM_019296 Cdc2a 1367776_at 203213_at CDC2
NM_019296 Cdc2a 1367776_at 210559_s_at CDC2
NM_019296 Cdc2a 1367776_at 203214_x_at CDC2
U05341 Cdc20 1387895_s_at 202870_s_at CDC20
NM_133572 Cdc25B 1370034_at 201853_s_at CDC25B
BF417638 Cdca3 1374449_at 221436_s_at CDCA3
AI013919 Cdkn1c 1372299_at 219533_at CDKN1C
AI013919 Cdkn1c 1372299_at 213183_s_at CDKN1C
AI013919 Cdkn1c 1372299_at 216894_x_at CDKN1C
AI013919 Cdkn1c 1372299_at 213182_x_at CDKN1C
AI013919 Cdkn1c 1372299_at 219534_x_at CDKN1C
AI013919 Cdkn1c 1372299_at 213348_at CDKN1C
AF474976 Cdkn2a 1369194_a_at 209644_x_at CDKN2A
AF474976 Cdkn2a 1369194_a_at 207039_at CDKN2A
AF474976 Cdkn2a 1369194_a_at 211156_at CDKN2A
NM_131902 Cdkn2c 1370054_at 204159_at CDKN2C
NM_131902 Cdkn2c 1370054_at 211792_s_at CDKN2C
BE113362 Cdkn3 1372685_at 209714_s_at CDKN3
AI576758 Scgf 1392672_at 211709_s_at CLEC11A
AI576758 Scgf 1392672_at 210783_x_at CLEC11A
AI576758 Scgf 1392672_at 205131_x_at CLEC11A
BG371721 Clpx 1398698_at 204809_at CLPX
BE107780 1398204_at 203575_at CSNK2A2
NM_022266 Ctgf 1367631_at 209101_at CTGF
NM_017286 Cyp11a1 1368468_at 204309_at CYP11A1
X00469 Cyp1a1 1370269_at 205749_at CYP1A1
D38381 Cyp3a18 1398307_at 211442_x_at CYP3A43
D38381 Cyp3a18 1398307_at 211440_x_at CYP3A43
D38381 Cyp3a18 1398307_at 207773_x_at CYP3A43
D38381 Cyp3a18 1398307_at 211441_x_at CYP3A43
NM_053679 Dffa 1389195_at 203277_at DFFA
Table W1. (continued )
Rat Accession
Number
Rat Gene Symbol Rat 230 2.0
Probe Set
Human HG-U133A
Probe Set
Human Gene Symbol
NM_053883 Dusp6 1387024_at 208892_s_at DUSP6
NM_053883 Dusp6 1387024_at 208891_at DUSP6
NM_053883 Dusp6 1387024_at 208893_s_at DUSP6
AI578135 Ect2 1383747_at 219787_s_at ECT2
BF284634 1390112_at 201842_s_at EFEMP1
BF284634 1390112_at 201843_s_at EFEMP1
BF418373 1393335_at 219454_at EGFL6
AI547942 1378721_at 201911_s_at FARP1
AI547942 1378721_at 201910_at FARP1
BI289400 Fes 1380621_at 205418_at FES
NM_053428 Fgf13 1368114_at 205110_s_at FGF13
NM_022603 Fgfbp1 1368349_at 205014_at FGFBP1
L19107 FGFR2 1388168_a_at 208229_at FGFR2
L19107 FGFR2 1388168_a_at 208228_s_at FGFR2
L19107 FGFR2 1388168_a_at 211399_at FGFR2
L19107 FGFR2 1388168_a_at 211401_s_at FGFR2
L19107 FGFR2 1388168_a_at 211398_at FGFR2
L19107 FGFR2 1388168_a_at 203639_s_at FGFR2
L19107 FGFR2 1388168_a_at 203638_s_at FGFR2
L19107 FGFR2 1388168_a_at 208234_x_at FGFR2
L19107 FGFR2 1388168_a_at 208225_at FGFR2
L19107 FGFR2 1388168_a_at 211400_at FGFR2
NM_021774 Fhit 1369318_at 206492_at FHIT
BE112403 1397648_at 221308_at FRS2
AI230396 Fyn 1373683_at 216033_s_at FYN
AI230396 Fyn 1373683_at 210105_s_at FYN
AI230396 Fyn 1373683_at 212486_s_at FYN
BI287978 Gadd45b 1372016_at 207574_s_at GADD45B
BI287978 Gadd45b 1372016_at 209305_s_at GADD45B
BI287978 Gadd45b 1372016_at 209304_x_at GADD45B
BI287978 Gadd45b 1372016_at 213560_at GADD45B
AI599423 Gadd45g 1388792_at 204121_at GADD45G
NM_017195 Gap43 1371287_at 216963_s_at GAP43
NM_017195 Gap43 1371287_at 204471_at GAP43
NM_017195 Gap43 1371287_at 216967_at GAP43
AJ131902 Gas7 1370963_at 210872_x_at GAS7
AJ131902 Gas7 1370963_at 211067_s_at GAS7
AJ131902 Gas7 1370963_at 202191_s_at GAS7
AJ131902 Gas7 1370963_at 207704_s_at GAS7
AJ131902 Gas7 1370963_at 202192_s_at GAS7
BI289525 Gdf1 1377506_at 206397_x_at GDF1
NM_017017 Hgf 1387701_at 210998_s_at HGF
NM_017017 Hgf 1387701_at 210997_at HGF
NM_017017 Hgf 1387701_at 210755_at HGF
NM_017017 Hgf 1387701_at 209960_at HGF
NM_017017 Hgf 1387701_at 209961_s_at HGF
BE119649 Hgfac 1381006_at 207027_at HGFAC
AI548958 1393790_at 219983_at HRASLS
AI548958 1393790_at 219984_s_at HRASLS
M15481 Igf1 1370333_a_at 209540_at IGF1
M15481 Igf1 1370333_a_at 209541_at IGF1
M15481 Igf1 1370333_a_at 211577_s_at IGF1
M15481 Igf1 1370333_a_at 209542_x_at IGF1
NM_012588 Igfbp3 1367652_at 210095_s_at IGFBP3
NM_012588 Igfbp3 1367652_at 212143_s_at IGFBP3
BE108969 Igfbp4 1371462_at 201508_at IGFBP4
AI233246 Igfbp7 1371357_at 201163_s_at IGFBP7
AI233246 Igfbp7 1371357_at 213910_at IGFBP7
AI233246 Igfbp7 1371357_at 201162_at IGFBP7
BE111697 Cdc23 1373722_at 218755_at KIF20A
BG381002 Lcmt1 1388747_at 221515_s_at LCMT1
AI229354 Lgi1 1386023_at 206349_at LGI1
BF412229 1398569_at 221640_s_at LRDD
AI716087 1375894_at 218437_s_at LZTFL1
AW143296 Mad2l1 1398602_at 203362_s_at MAD2L1
NM_019318 Maf 1385243_at 209348_s_at MAF
NM_019318 Maf 1385243_at 209347_s_at MAF
NM_019318 Maf 1385243_at 206363_at MAF
AI714002 Mki67 1374775_at 212022_s_at MKI67
AI714002 Mki67 1374775_at 212023_s_at MKI67
AI714002 Mki67 1374775_at 212021_s_at MKI67
AI714002 Mki67 1374775_at 212020_s_at MKI67
Table W1. (continued )
Rat Accession
Number
Rat Gene Symbol Rat 230 2.0
Probe Set
Human HG-U133A
Probe Set
Human Gene Symbol
BE115673 1392086_at 203037_s_at MTSS1
BE115673 1392086_at 203036_s_at MTSS1
BE115673 1392086_at 210360_s_at MTSS1
BE115673 1392086_at 210359_at MTSS1
NM_012603 Myc 1368308_at 202431_s_at MYC
BI300996 Mycl1 1395781_at 214058_at MYCL1
BI300996 Mycl1 1395781_at 215491_at MYCL1
NM_133583 Ndrg2 1387121_a_at 214279_s_at NDRG2
NM_133583 Ndrg2 1387121_a_at 214278_s_at NDRG2
NM_133583 Ndrg2 1387121_a_at 206453_s_at NDRG2
BG666709 Ndr4 1370229_at 209159_s_at NDRG4
NM_021589 Ntrk1 1369000_at 208605_s_at NTRK1
NM_019210 Pak3 1368902_at 214607_at PAK3
U05989 Pawr 1368702_at 204005_s_at PAWR
U05989 Pawr 1368702_at 204004_at PAWR
U05989 Pawr 1368702_at 214237_x_at PAWR
U05989 Pawr 1368702_at 214090_at PAWR
BE100812 Pdgfa 1379375_at 205463_s_at PDGFA
BE100812 Pdgfa 1379375_at 216867_s_at PDGFA
NM_031317 Pdgfc 1392274_at 218718_at PDGFC
BM389426 Pdgfrb 1370642_s_at 202273_at PDGFRB
BM384311 1374616_at 205226_at PDGFRL
U10188 Plk1 1370297_at 202240_at PLK1
U10188 Plk1 1370297_at 201429_s_at PLK1 (RPL37A)
BE109322 Plk4 1377832_at 204886_at PLK4
BE109322 Plk4 1377832_at 204887_s_at PLK4
BE109322 Plk4 1377832_at 211088_s_at PLK4
NM_013196 Ppara 1394800_at 210771_at PPARA
NM_013196 Ppara 1394800_at 206870_at PPARA
NM_013124 Pparg 1369179_a_at 208510_s_at PPARG
AA891940 Arhc 1371659_at 200885_at PPM1J
BI282953 Pycard 1389873_at 221666_s_at PYCARD
NM_053459 Rab27b 1370122_at 207017_at RAB27B
NM_053459 Rab27b 1370122_at 207018_s_at RAB27B
AA924620 Rab40b 1383826_at 204547_at RAB40B
AA924620 Rab40b 1383826_at 217597_x_at RAB40B
AI409259 Racgap1 1373658_at 222077_s_at RACGAP1
BF284067 1373631_at 203911_at RAP1GAP
BF284067 1373631_at 210618_at RAP1GAP
NM_133410 Rap2b 1392922_at 213923_at RAP2B
NM_133410 Rap2b 1392922_at 214487_s_at RAP2B
NM_133410 Rap2b 1392922_at 214488_at RAP2B
AI237779 Rasa3 1392224_at 206221_at RASA3
AI237779 Rasa3 1392224_at 206220_s_at RASA3
AW532114 Rasgrp2 1374872_at 214367_at RASGRP2
AW532114 Rasgrp2 1374872_at 214368_at RASGRP2
AW532114 Rasgrp2 1374872_at 214369_s_at RASGRP2
AW532114 Rasgrp2 1374872_at 208206_s_at RASGRP2
AA955648 Arhd 1382197_at 209885_at RHOD
AA955648 Arhd 1382197_at 31846_at RHOD
BE097238 RICS 1377061_at 210791_s_at RICS
BE097238 RICS 1377061_at 203431_s_at RICS
AI706777 Rin3 1375020_at 60471_at RIN3
AI706777 Rin3 1375020_at 219457_s_at RIN3
AI706777 Rin3 1375020_at 219456_s_at RIN3
AI706777 Rin3 1375020_at 220439_at RIN3
AI144754 Rnd1 1381533_at 210056_at RND1
AI235414 1377029_at 210479_s_at RORA
AI235414 1377029_at 210426_x_at RORA
BE110171 1379833_at 206419_at RORC
NM_021865 Jundp1 1369891_at 220358_at SNFT
NM_021578 Tgfb1 1370082_at 203085_s_at TGFB1
NM_021578 Tgfb1 1370082_at 203084_at TGFB1
NM_031131 Tgfb2 1387172_a_at 220407_s_at TGFB2
NM_031131 Tgfb2 1387172_a_at 209908_s_at TGFB2
NM_031131 Tgfb2 1387172_a_at 220406_at TGFB2
BI283829 Hdgfrp3 1379482_at 219892_at TM6SF1
NM_012870 Tnfrsf11b 1369407_at 204933_s_at TNFRSF11B
NM_012870 Tnfrsf11b 1369407_at 204932_at TNFRSF11B
BI303379 Tnfrsf12a 1371785_at 218368_s_at TNFRSF12A
AA800814 Tnfsf13 1377353_a_at 210314_x_at TNFSF13
AA800814 Tnfsf13 1377353_a_at 209500_x_at TNFSF13
Table W1. (continued )
Rat Accession
Number
Rat Gene Symbol Rat 230 2.0
Probe Set
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AA800814 Tnfsf13 1377353_a_at 209499_x_at TNFSF13
AA800814 Tnfsf13 1377353_a_at 211495_x_at TNFSF13
AA900477 1384170_at 205537_s_at VAV2
AA900477 1384170_at 205536_at VAV2
NM_053653 Vegfc 1368463_at 209946_at VEGFC
NM_031534 Wt1 1369695_at 206067_s_at WT1
NM_031534 Wt1 1369695_at 216953_s_at WT1
Mouse Accession
Number
Mouse Gene Mouse MG-74Av2
Probe Set
Rat Accession
Number
Rat Gene Symbol Rat 230 2.0
Probe Set
Human HG-U133A
Probe Set
Human Gene Symbol
AF002823 Bub1 104097_at BF388785 Bub1 1385086_at 209642_at BUB1
AF002823 Bub1 104097_at BF388785 Bub1 1385086_at 216277_at BUB1
AF002823 Bub1 104097_at BF388785 Bub1 1385086_at 216275_at BUB1
AF002823 Bub1 104097_at BF388785 Bub1 1385086_at 215509_s_at BUB1
AF002823 Bub1 104097_at BF388785 Bub1 1385086_at 215508_at BUB1
X75483 Ccna2 99186_at AA998516 Ccna2 1379582_a_at 213226_at CCNA2
X75483 Ccna2 99186_at AA998516 Ccna2 1379582_a_at 203418_at CCNA2
X66032 Ccnb2 94294_at AW253821 Ccnb2 1389566_at 202705_at CCNB2
AI849928 Ccnd1 94232_at X75207 Ccnd1 1371150_at 208712_at CCND1
AI849928 Ccnd1 94232_at X75207 Ccnd1 1371150_at 208711_s_at CCND1
M38724 CDC2a 100128_at NM_019296 Cdc2a 1367776_at 203213_at CDC2
M38724 CDC2a 100128_at NM_019296 Cdc2a 1367776_at 210559_s_at CDC2
M38724 CDC2a 100128_at NM_019296 Cdc2a 1367776_at 203214_x_at CDC2
AW061324 CDC20 96319_at U05341 Cdc20 1387895_s_at 202870_s_at CDC20
AV138783 Gadd45b 161666_f_at BI287978 Gadd45b 1372016_at 207574_s_at GADD45B
AV138783 Gadd45b 161666_f_at BI287978 Gadd45b 1372016_at 209305_s_at GADD45B
AV138783 Gadd45b 161666_f_at BI287978 Gadd45b 1372016_at 209304_x_at GADD45B
AV138783 Gadd45b 161666_f_at BI287978 Gadd45b 1372016_at 213560_at GADD45B
U83902 Mad2l1 99632_at AW143296 Mad2l1 1398602_at 203362_s_at MAD2L1
AB033921 Ndr2 96088_at NM_133583 Ndrg2 1387121_a_at 214279_s_at NDRG2
AB033921 Ndr2 96088_at NM_133583 Ndrg2 1387121_a_at 214278_s_at NDRG2
AB033921 Ndr2 96088_at NM_133583 Ndrg2 1387121_a_at 206453_s_at NDRG2
U01063 Plk 93099_f_at U10188 Plk1 1370297_at 202240_at PLK1
U01063 Plk 93099_f_at U10188 Plk1 1370297_at 201429_s_at PLK1 (RPL37A)
AW122347 Racgap1 94953_at AI409259 Racgap1 1373658_at 222077_s_at RACGAP1
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